.png){kind=icon}
Return
Statins and Cognitive Function
.png){kind=icon}
PRE
AI
DOI：10.7326/0003-4819-159-10-201311190-00007.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Background: Despite the U. S. Food and Drug Administration (FDA) warning regarding cognitive impairment, the relationship between statins and cognition remains unknown. Purpose: To examine the effect of statins on cognition. Data Sources: PubMed, Embase, and Cochrane Library from inception through October 2012; FDA databases from January 1986 through March 2012. Study Selection: Randomized, controlled trials (RCTs) and cohort, case-control, and cross-sectional studies evaluating cognition in patients receiving statins. Data Extraction: Two reviewers extracted data, 1 reviewer assessed study risk of bias, and 1 reviewer checked all assessments. Data Synthesis: Among statin users, low-quality evidence suggested no increased incidence of Alzheimer disease and no difference in cognitive performance related to procedural memory, attention, or motor speed. Moderate-quality evidence suggested no increased incidence of dementia or mild cognitive impairment or any change in cognitive performance related to global cognitive performance scores, executive function, declarative memory, processing speed, or visuoperception. Examination of the FDA post-marketing surveillance databases revealed a low reporting rate for cognitive-related adverse events with statins that was similar to the rates seen with other commonly prescribed cardiovascular medications. Limitations: The absence of many well-powered RCTs for most outcomes resulted in final strengths of evidence that were low or moderate. Imprecision, inconsistency, and risk of bias also limited the strength of findings. Conclusion: Larger and better-designed studies are needed to draw unequivocal conclusions about the effect of statins on cognition. Published data do not suggest an adverse effect of statins on cognition; however, the strength of available evidence is limited, particularly with regard to high-dose statins.
Keywords:
LIPID-LOWERING AGENTS
MODERATE ALZHEIMER-DISEASE
QUALITY-OF-LIFE
INCIDENT DEMENTIA
CONTROLLED-TRIAL
REDUCED RISK
DOUBLE-BLIND
MEMORY LOSS
PRAVASTATIN
SIMVASTATIN
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
15.2
Papers:
4.2W
Citations:
6.5W
Organization
No organization information available
Cited Papers
ShareSave
ShareSaveShareSaveTreatment of vascular risk factors is associated with slower decline in Alzheimer disease.png)
NEUROLOGY
NEUROLOGYIF8.5
PREAI
ShareSaveShareSaveShareSaveShareSaveTime of ball possession and visual search in the decision-making on shooting in the sport of futsal
PREAI
ShareSave
View more